Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Tao Q, Li X, Zhu T, et al. Lactate transporter SLC16A3 (MCT4) as an onco-immunological biomarker associating tumor microenvironment and immune responses in lung cancer. Int J Gen Med. 2022;15:4465–4474. doi:10.2147/ijgm.s353592
   PubMed Web of Science ®Google Scholar
• Jahanzeb M, Lin HM, Pan X, et al. Immunotherapy treatment patterns and outcomes among ALK-positive patients with non-small-cell lung cancer. Clin Lung Cancer. 2021;22(1):49–57. doi:10.1016/j.cllc.2020.08.003
   PubMed Web of Science ®Google Scholar
• Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, Phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–733. doi:10.1200/jco.20.01605
   PubMed Web of Science ®Google Scholar
• Huang MY, Jiang XM, Wang BL, Sun Y, Lu JJ. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacol Ther. 2021;219:107694. doi:10.1016/j.pharmthera.2020.107694
   PubMed Web of Science ®Google Scholar
• Franchi M, Pellegrini G, Corrao G. Effectiveness and cost-effectiveness profile of second-line treatments with nivolumab, pembrolizumab and atezolizumab in patients with advanced non-small cell lung cancer. Pharmaceuticals. 2022;15(4):489. doi:10.3390/ph15040489
   Web of Science ®Google Scholar
• Wang L, Yang Y, Yu J, et al. Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: a systematic review and network meta-analysis. Thorac Cancer. 2022;13(3):322–337. doi:10.1111/1759-7714.14244
   PubMed Web of Science ®Google Scholar
• Wu HX, Pan YQ, He Y, et al. Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1-expressing esophageal squamous cell carcinoma: a post hoc analysis of JUPITER-06 and meta-analysis. J Clin Oncol. 2023;41(9):1735–1746. doi:10.1200/jco.22.01490
   PubMed Web of Science ®Google Scholar
• Zhou ZC, Chen KY, Li N, et al. Real-world utilization of PD-1/PD-L1 inhibitors with palliative radiotherapy in patients with metastatic non-small cell lung cancer. Thorac Cancer. 2022;13(16):2291–2300. doi:10.1111/1759-7714.14553
   PubMed Web of Science ®Google Scholar
• Giaj Levra M, Cotté FE, Corre R, et al. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer. 2020;140:99–106. doi:10.1016/j.lungcan.2019.12.017
   PubMed Web of Science ®Google Scholar
• Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review. Thorac Cancer. 2020;11(7):1927–1933. doi:10.1111/1759-7714.13483
   PubMed Web of Science ®Google Scholar
• Gobbini E, Toffart AC, Pérol M, et al. Immune checkpoint inhibitors rechallenge efficacy in non-small-cell lung cancer patients. Clin Lung Cancer. 2020;21(5):e497–e510. doi:10.1016/j.cllc.2020.04.013
   PubMed Web of Science ®Google Scholar
• Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised Phase 3 trial. Lancet Oncol. 2013;14(1):29–37. doi:10.1016/s1470-2045(12)70477-1
   PubMed Web of Science ®Google Scholar
• Feng Y, Tao Y, Chen H, et al. Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: a systematic review and meta-analysis. Thorac Cancer. 2023;14(25):2536–2547. doi:10.1111/1759-7714.15063
   PubMed Web of Science ®Google Scholar
• Hall RD, Le TM, Haggstrom DE, Gentzler RD. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015;4(5):515–523. doi:10.3978/j.issn.2218-6751.2015.06.09
   PubMed Web of Science ®Google Scholar
• Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109(4):1207–1219. doi:10.1111/cas.13536
   PubMed Web of Science ®Google Scholar
• Fei Z, Rui M, Wang Y, Ma A. Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China. Expert Rev Pharmacoecon Outcomes Res. 2023;23(1):79–87. doi:10.1080/14737167.2023.2144837
   PubMed Web of Science ®Google Scholar
• Wang P, Fang X, Yin T, et al. Efficacy and safety of anti-PD-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-a retrospective study. Front Oncol. 2021;11:628124. doi:10.3389/fonc.2021.628124
   PubMed Web of Science ®Google Scholar
• Jin R, Liu C, Zheng S, et al. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Cancer Biol Med. 2020;17(3):768–781. doi:10.20892/j.issn.2095-3941.2020.0121
   PubMed Web of Science ®Google Scholar
• Sun X, Xu J, Xie L, Guo W. Effectiveness and tolerability of anlotinib plus PD-1 inhibitors for patients with previously treated metastatic soft-tissue sarcoma. Int J Gen Med. 2022;15:7581–7591. doi:10.2147/ijgm.s379269
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Yu L, Xu J, Qiao R, et al. Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer. Cancer Med. 2023;12(5):5372–5383. doi:10.1002/cam4.5360
   PubMed Web of Science ®Google Scholar
• Cascone T, Fradette J, Pradhan M, Gibbons DL. Tumor immunology and immunotherapy of non-small-cell lung cancer. Cold Spring Harb Perspect Med. 2022;12(5):a037895. doi:10.1101/cshperspect.a037895
   PubMed Web of Science ®Google Scholar
• Ren S, Chen J, Xu X, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a Phase 3 trial. J Thorac Oncol. 2022;17(4):544–557. doi:10.1016/j.jtho.2021.11.018
   PubMed Web of Science ®Google Scholar
• Lu Y, Xu M, Guan L, et al. PD-1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment for advanced esophageal cancer: a systematic review and meta-analysis. J Immunother. 2022;45(5):243–253. doi:10.1097/cji.0000000000000420
   PubMed Web of Science ®Google Scholar
• Bersanelli M, Buti S, Giannarelli D, et al. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: the multicenter retrospective CLARITY study. Lung Cancer. 2020;150:123–131. doi:10.1016/j.lungcan.2020.10.008
   PubMed Web of Science ®Google Scholar
• Chu T, Zhong R, Zhong H, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol. 2021;16(4):643–652. doi:10.1016/j.jtho.2020.11.026
   PubMed Web of Science ®Google Scholar
• Cheng JD, Chai LX, Zhao ZP, Hao YY, Li S. Efficacy and safety of anlotinib for patients with advanced NSCLC who progressed after standard regimens and the preliminary analysis of an efficacy predictor. Cancer Manag Res. 2020;12:5641–5650. doi:10.2147/cmar.s253366
   PubMed Web of Science ®Google Scholar
• Gobbini E, Charles J, Toffart AC, et al. Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients. Bull Cancer. 2020;107(11):1098–1107. doi:10.1016/j.bulcan.2020.07.009
   PubMed Web of Science ®Google Scholar
• Gandara DR, von Pawel J, Mazieres J, et al. Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, Phase III OAK Study. J Thorac Oncol. 2018;13(12):1906–1918. doi:10.1016/j.jtho.2018.08.2027
   PubMed Web of Science ®Google Scholar
• Xu Z, Hao X, Yang K, et al. Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study. J Cancer Res Clin Oncol. 2022;148(11):3081–3089. doi:10.1007/s00432-021-03901-2
   PubMed Web of Science ®Google Scholar
• Zhai C, Zhang X, Ren L, et al. The efficacy and safety of anlotinib combined with PD-1 antibody for third-line or further-line treatment of patients with advanced non-small-cell lung cancer. Front Oncol. 2020;10:619010. doi:10.3389/fonc.2020.619010
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang C, Yang S, et al. Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study. Future Oncol. 2021;17(31):4091–4099. doi:10.2217/fon-2021-0649
   PubMed Web of Science ®Google Scholar
• Lamplugh Z, Fan Y. Vascular microenvironment, tumor immunity and immunotherapy. Front Immunol. 2021;12:811485. doi:10.3389/fimmu.2021.811485
   PubMed Web of Science ®Google Scholar
• Guo F, Cui J. Anti-angiogenesis: opening a new window for immunotherapy. Life Sci. 2020;258:118163. doi:10.1016/j.lfs.2020.118163
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.3039
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi:10.1016/s0140-6736(15)01281-7
   PubMed Web of Science ®Google Scholar
• Jiang HT, Li W, Zhang B, Gong Q, Qie HL. Efficacy and safety of anlotinib monotherapy as third-line therapy for elderly patients with non-small cell lung cancer: a real-world exploratory study. Int J Gen Med. 2021;14:7625–7637. doi:10.2147/ijgm.s334436
   PubMed Web of Science ®Google Scholar
• Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res. 2018;6(9):1093–1099. doi:10.1158/2326-6066.cir-17-0755
   PubMed Web of Science ®Google Scholar
• Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461–2471. doi:10.1016/s0140-6736(17)31827-5
   PubMed Web of Science ®Google Scholar
• Vitale G, Lamberti G, Comito F, et al. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. Expert Opin Biol Ther. 2020;20(9):1047–1059. doi:10.1080/14712598.2020.1762562
   PubMed Web of Science ®Google Scholar